about
The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cellsPrimer: inflammasomes and interleukin 1beta in inflammatory disordersA family with Papillon-Lefevre syndrome reveals a requirement for cathepsin C in granzyme B activation and NK cell cytolytic activityHuman tumour immune evasion via TGF-β blocks NK cell activation but not survival allowing therapeutic restoration of anti-tumour activity.Licensed human natural killer cells aid dendritic cell maturation via TNFSF14/LIGHTCUB domain containing protein 1 (CDCP1) modulates adhesion and motility in colon cancer cells.Creation of mice expressing human antibody light chains by introduction of a yeast artificial chromosome containing the core region of the human immunoglobulin kappa locus.Profiling killers; unravelling the pathways of human natural killer cell function.Cytotoxic and immune-mediated killing of human colorectal cancer by reovirus-loaded blood and liver mononuclear cellsThe NLRP3 inflammasome, a target for therapy in diverse disease states.Blocking oncogenic RAS enhances tumour cell surface MHC class I expression but does not alter susceptibility to cytotoxic lymphocytes.Altered natural killer cell subset homeostasis and defective chemotactic responses in paroxysmal nocturnal hemoglobinuria.TLR dependent XBP-1 activation induces an autocrine loop in rheumatoid arthritis synoviocytes.Detecting variable (V), diversity (D) and joining (J) gene segment recombination using a two-colour fluorescence system.A human NK cell activation/inhibition threshold allows small changes in the target cell surface phenotype to dramatically alter susceptibility to NK cells.Identification of the BCL2/adenovirus E1B-19K protein-interacting protein 2 (BNIP-2) as a granzyme B target during human natural killer cell-mediated killing.A flow cytometric assay for analysis of natural-killer cell-mediated cytolysis of adenovirus-transformed cells.Expression of the CUB domain containing protein 1 (CDCP1) gene in colorectal tumour cells.Differential expression of LFA-3, Fas and MHC Class I on Ad5- and Ad12-transformed human cells and their susceptibility to lymphokine-activated killer (LAK) cells.Controlled infection with a therapeutic virus defines the activation kinetics of human natural killer cells in vivo.A homozygous STIM1 mutation impairs store-operated calcium entry and natural killer cell effector function without clinical immunodeficiency.Haematopoietic repopulating activity in human cord blood CD133+ quiescent cells.Proteolytic activation of the cytotoxic phenotype during human NK cell development.Natural killer (NK) cell function in paroxysmal nocturnal hemoglobinuria: a deficiency of NK cells, but not an NK cell deficiency.Blood Coagulation Factor X Exerts Differential Effects on Adenovirus Entry into Human Lymphocytes.Human immunoglobulin VH and D segments on chromosomes 15q11.2 and 16p11.2.Evidence of NLRP3-inflammasome activation in rheumatoid arthritis (RA); genetic variants within the NLRP3-inflammasome complex in relation to susceptibility to RA and response to anti-TNF treatment.Antibody repertoires of four- and five-feature translocus mice carrying human immunoglobulin heavy chain and kappa and lambda light chain yeast artificial chromosomes.Regulated activity of the IgH intron enhancer (E mu) in the T lymphocyte lineage.β-Catenin-mediated immune evasion pathway frequently operates in primary cutaneous melanomas.Cancer and the immune system: an overview.High-risk human papillomavirus E7 expression reduces cell-surface MHC class I molecules and increases susceptibility to natural killer cells.Lymphodepletion in the ApcMin/+ mouse model of intestinal tumorigenesis.Safety and Clinical Effect of Subcutaneous Human Interleukin-21 in Patients with Metastatic Melanoma or Renal Cell Carcinoma: A Phase I TrialPapillon-Lefèvre Syndrome and Malignant MelanomaA second B cell-specific enhancer 3' of the immunoglobulin heavy-chain locusGenetic and Environmental Determinants of Immune Response to Cutaneous MelanomaExpression profiling of single cells and patient cohorts identifies multiple immunosuppressive pathways and an altered NK cell phenotype in glioblastoma
P50
Q28249199-95C19328-6C50-408C-B0FB-0F1EA7395F53Q28263370-750A62EC-74A1-44D5-AF03-7C749EA3E101Q28291571-B5825F45-7467-4B9B-B080-4759FEF8839BQ34016504-35CAAE32-57EA-4713-9AEF-15C801B87DABQ34831085-55200DFD-153A-4E34-A27A-808F6CE96B63Q35318420-3619F67C-2E32-4EB4-8A8D-70549B597F90Q36705203-3AC5946D-053F-4061-BF50-10514331EB29Q37061635-2AD0E1E3-74EA-47EA-8096-0DAE289D4C79Q37477574-8EA4C2BB-2113-4F44-90CF-D916105B473BQ37702149-D0BFD6D8-3B72-443E-A27C-AB73E78B26DDQ39040777-C0AF8AE5-D20D-4F8B-AF4D-87772969B5EFQ39120969-7F8C99B4-660E-4CB4-9390-844CE53E9B0CQ39306114-47441BCD-1572-46AC-8C6A-B0A9CFE1E7E0Q39434942-7CCFBF7C-7A9F-455B-8045-C11A6FF20550Q39614580-B7E8246B-4D59-492D-BE74-F6D2049E366FQ39668299-15D1D51A-A9FE-4707-8F4F-9EA4B16182A4Q40101823-5EF29C8D-6221-4BD3-97AD-33F6611E9649Q40163759-B2BA9068-1801-49DE-A084-02280F345CF7Q40408075-50F81F59-FBE3-408B-8510-AF99C3A9E931Q41621228-AE157D7C-8089-4C88-B94A-C43C05D00D8DQ42624654-1B4FD78C-E492-485B-A611-765E614C433CQ44303809-AAFC313E-E23D-4AFF-86B5-FD49B9B42A7AQ45943487-3EC688CE-8DBC-4B3B-A3B0-6A675CEADB9AQ46179652-B9C9291B-EA1E-42AD-BAE5-03C14D9B5D21Q47232092-6BD05B49-9F62-4600-BA4D-F8C7BA88B51FQ48082220-DC65DDE7-BCE9-4CE0-919F-A433C4F00CCBQ50980583-8C234E28-1653-47DE-AA8C-C7AB1D1E35CEQ52172777-EA59E232-DE7E-4000-AA07-E6AEB73967C7Q52211618-16B64C76-4447-463A-8C0E-D8A9B307E1A9Q52801913-36F3168D-719C-4A23-980D-401F454DDA1AQ52850729-04E9799C-3E1B-4BEA-84B3-B0EA5BCBF27BQ52852974-20B6D1F0-59E9-4BDC-BCB7-D6F37253AA97Q52859781-E23FE863-8E60-469E-AED0-0427A2C546D4Q56838211-68A4C8FC-0D8B-491E-A708-B3FA77983BB2Q56838214-0B00ADD6-D682-4461-A906-2F7393993232Q56838225-94BABAD2-7224-48A9-AC0C-88A6A8ED090DQ61846321-C10B0575-0CC2-40BF-B205-03724317428DQ91562290-F7C302CD-F518-4E01-A3BC-7B05ED12B8CF
P50
description
chercheur
@fr
hulumtues
@sq
investigador
@es
rannsaichear
@gd
researcher
@en
researcher
@en-ca
researcher
@en-gb
ricercatore
@it
taighdeoir
@ga
tutkija
@fi
name
Graham Cook
@br
Graham Cook
@cy
Graham Cook
@de
Graham Cook
@en-ca
Graham Cook
@en-gb
Graham Cook
@es
Graham Cook
@fi
Graham Cook
@fr
Graham Cook
@ga
Graham Cook
@gd
type
label
Graham Cook
@br
Graham Cook
@cy
Graham Cook
@de
Graham Cook
@en-ca
Graham Cook
@en-gb
Graham Cook
@es
Graham Cook
@fi
Graham Cook
@fr
Graham Cook
@ga
Graham Cook
@gd
altLabel
Graham Cook
@en
Graham P Cook
@en
prefLabel
Graham Cook
@br
Graham Cook
@cy
Graham Cook
@de
Graham Cook
@en-ca
Graham Cook
@en-gb
Graham Cook
@es
Graham Cook
@fi
Graham Cook
@fr
Graham Cook
@ga
Graham Cook
@gd
P106
P1153
7401954763
P21
P31
P496
0000-0003-0223-3652